Update - Wholesale cost of Zarxio will be 15% less than Amgen's Neupogen
Biosimilars land in the US as Sandoz launches Zarxio
Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.